# AKI Protocol â€“ Acute Kidney Injury & Dialysis Management with Virtua Voorhees Addenda
## Final Version with Integrated Diagnostic Calculators

**Primary Guideline:** KDIGO Acute Kidney Injury Work Group Guidelines 2024
**Official Source:** https://kdigo.org/guidelines/acute-kidney-injury
**Supporting Guidelines:** 
- AAFP Clinical Guidelines for Acute Kidney Injury 2019
- KDOQI Clinical Practice Guidelines for Hemodialysis 2023
- MDCalc Clinical Decision Support Tools

## ENHANCED DYNAMIC CARD SYSTEM WITH INTEGRATED CALCULATORS

### Card 0 â€“ Initial AKI Assessment (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”¬ ACUTE KIDNEY INJURY ASSESSMENT       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š KDIGO AKI STAGING:                   â”‚
â”‚ â€¢ Stage 1: Cr 1.5-1.9Ã— baseline OR     â”‚
â”‚   â‰¥26.5Î¼mol/L increase, UOP <0.5mL/kg/hâ”‚
â”‚ â€¢ Stage 2: Cr 2.0-2.9Ã— baseline        â”‚
â”‚ â€¢ Stage 3: Cr â‰¥3Ã— baseline OR â‰¥353.6Î¼mol/Lâ”‚
â”‚   OR initiation of RRT OR anuria â‰¥12h  â”‚
â”‚                                         â”‚
â”‚ ğŸš¨ Immediate drug chart review needed   â”‚
â”‚                                         â”‚
â”‚ â“ Does patient meet AKI criteria?      â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Investigate causes            â”‚
â”‚ ğŸ”˜ NO â†’ Monitor renal function         â”‚
â”‚                                         â”‚
â”‚ [Next: Based on Selection â–¶]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1A â€“ Investigate AKI (Node C â†’ Investigations)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ” AKI INVESTIGATION PROTOCOL           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Drug chart modifications:            â”‚
â”‚ â€¢ Hold metformin                       â”‚
â”‚ â€¢ Hold diuretics                       â”‚
â”‚ â€¢ Hold ACE/ARBs                        â”‚
â”‚ â€¢ Hold NSAIDs                          â”‚
â”‚ â€¢ Avoid IV contrast                    â”‚
â”‚ â€¢ Review antimicrobials dosing         â”‚
â”‚   (aminoglycosides, vancomycin,        â”‚
â”‚   aciclovir, amphotericin, foscarnet)  â”‚
â”‚                                         â”‚
â”‚ ğŸ“‹ Essential investigations ordered:    â”‚
â”‚ â€¢ FBC, U&E, CRP, CaÂ²âº, POâ‚„Â³â», MgÂ²âº    â”‚
â”‚ â€¢ VBG, LFT, clot, CK                   â”‚
â”‚ â€¢ Urinalysis with microscopy           â”‚
â”‚ â€¢ Urine electrolytes (Na+, Cr for FENa)â”‚
â”‚                                         â”‚
â”‚ [Next: Etiology determination â–¶]       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Initial Assessment]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1B â€“ Monitor Function (Node Monitor - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ˆ RENAL FUNCTION MONITORING            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Trend monitoring:                    â”‚
â”‚ â€¢ Baseline creatinine established      â”‚
â”‚ â€¢ No acute rise detected              â”‚
â”‚ â€¢ Continue routine monitoring          â”‚
â”‚                                         â”‚
â”‚ âš ï¸  Watch for progression:              â”‚
â”‚ â€¢ Daily creatinine if at risk          â”‚
â”‚ â€¢ Urine output monitoring              â”‚
â”‚ â€¢ Nephrotoxin avoidance                â”‚
â”‚                                         â”‚
â”‚ âœ… FUNCTION MONITORING ACTIVE          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Initial Assessment]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ Etiology Determination (Node Investigations â†’ Etiology)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”¬ AKI ETIOLOGY ASSESSMENT              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ©º Clinical evaluation:                 â”‚
â”‚ â€¢ Volume status assessment             â”‚
â”‚ â€¢ Medication review completed          â”‚
â”‚ â€¢ Systemic illness evaluation          â”‚
â”‚ â€¢ Urinary obstruction screening        â”‚
â”‚                                         â”‚
â”‚ ğŸ§ª Urinalysis interpretation:           â”‚
â”‚ â€¢ Bland sediment â†’ Prerenal likely     â”‚
â”‚ â€¢ Muddy brown casts â†’ ATN              â”‚
â”‚ â€¢ RBC casts â†’ Glomerulonephritis       â”‚
â”‚ â€¢ WBC casts â†’ Interstitial nephritis   â”‚
â”‚                                         â”‚
â”‚ â“ Prerenal vs intrinsic unclear?       â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ FENa/FEUrea calculators       â”‚
â”‚ ğŸ”˜ NO â†’ Proceed to specific management â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2B â€“ Direct Management (Node Specific Mgmt)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¯ DIRECT AKI MANAGEMENT                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“‹ Clear etiology identified:           â”‚
â”‚ â€¢ Prerenal: Volume resuscitation       â”‚
â”‚ â€¢ ATN: Supportive care                 â”‚
â”‚ â€¢ Glomerular: Consider biopsy          â”‚
â”‚ â€¢ Obstructive: Relieve obstruction     â”‚
â”‚                                         â”‚
â”‚ ğŸ¥ Nephrology consultation if:          â”‚
â”‚ â€¢ Unclear intrinsic cause              â”‚
â”‚ â€¢ Rapidly progressive GN suspected     â”‚
â”‚ â€¢ Severe AKI (Stage 3)                 â”‚
â”‚                                         â”‚
â”‚ [Next: Risk stratification â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Etiology Determination]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ FENa Calculator (Node Calculator Modal)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ§® FRACTIONAL EXCRETION OF SODIUM      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Required values:                     â”‚
â”‚ â€¢ Serum Creatinine: [___] mg/dL        â”‚
â”‚ â€¢ Serum Sodium: [___] mEq/L            â”‚
â”‚ â€¢ Urine Creatinine: [___] mg/dL        â”‚
â”‚ â€¢ Urine Sodium: [___] mEq/L            â”‚
â”‚                                         â”‚
â”‚ ğŸ”¢ Formula:                             â”‚
â”‚ FENa = (UNaÃ—SCr)/(UCrÃ—SNa) Ã— 100       â”‚
â”‚                                         â”‚
â”‚ ğŸ“ˆ Result: [__._]%                      â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Interpretation:                      â”‚
â”‚ â€¢ <1%: Prerenal AKI                    â”‚
â”‚ â€¢ >2%: Intrinsic renal disease (ATN)   â”‚
â”‚ â€¢ 1-2%: Indeterminate (use FEUrea)     â”‚
â”‚                                         â”‚
â”‚ â“ FENa result interpretation?          â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ <1% â†’ Prerenal management           â”‚
â”‚ ğŸ”˜ >2% â†’ ATN management                â”‚
â”‚ ğŸ”˜ 1-2% â†’ Check FEUrea calculator      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3B â€“ FEUrea Calculator (Node Calculator Modal)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ§® FRACTIONAL EXCRETION OF UREA        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Required values:                     â”‚
â”‚ â€¢ Serum BUN: [___] mg/dL               â”‚
â”‚ â€¢ Serum Creatinine: [___] mg/dL        â”‚
â”‚ â€¢ Urine BUN: [___] mg/dL               â”‚
â”‚ â€¢ Urine Creatinine: [___] mg/dL        â”‚
â”‚                                         â”‚
â”‚ ğŸ”¢ Formula:                             â”‚
â”‚ FEUrea = (UBunÃ—SCr)/(UCrÃ—SBun) Ã— 100   â”‚
â”‚                                         â”‚
â”‚ ğŸ“ˆ Result: [__._]%                      â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Interpretation:                      â”‚
â”‚ â€¢ â‰¤35%: Prerenal AKI                   â”‚
â”‚ â€¢ >50%: Intrinsic renal disease        â”‚
â”‚ â€¢ 35-50%: Indeterminate                â”‚
â”‚                                         â”‚
â”‚ ğŸ’¡ More accurate than FENa if:          â”‚
â”‚ â€¢ Patient on diuretics                 â”‚
â”‚ â€¢ Chronic kidney disease               â”‚
â”‚                                         â”‚
â”‚ â“ FEUrea result interpretation?        â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ â‰¤35% â†’ Prerenal management          â”‚
â”‚ ğŸ”˜ >50% â†’ ATN management               â”‚
â”‚ ğŸ”˜ 35-50% â†’ Clinical judgment needed   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Prerenal Management (Node Prerenal â†’ Volume)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©¸ PRERENAL AKI MANAGEMENT              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’§ Volume assessment & resuscitation:   â”‚
â”‚ â€¢ Assess volume status clinically      â”‚
â”‚ â€¢ Isotonic crystalloid (LR preferred)  â”‚
â”‚ â€¢ Initial bolus: 500mL-1L over 30min   â”‚
â”‚ â€¢ Target MAP â‰¥65 mmHg                  â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitor response:                    â”‚
â”‚ â€¢ Urine output improvement             â”‚
â”‚ â€¢ Creatinine stabilization/improvement â”‚
â”‚ â€¢ Hemodynamic parameters               â”‚
â”‚                                         â”‚
â”‚ âš ï¸  Avoid overresuscitation:            â”‚
â”‚ â€¢ Stop if signs of volume overload     â”‚
â”‚                                         â”‚
â”‚ â“ Response to fluid resuscitation?     â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ GOOD â†’ Continue supportive care     â”‚
â”‚ ğŸ”˜ POOR â†’ Reassess etiology           â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4B â€“ ATN Management (Node ATN â†’ Support)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ«˜ ACUTE TUBULAR NECROSIS MANAGEMENT    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ›¡ï¸  Supportive care measures:           â”‚
â”‚ â€¢ Maintain euvolemia                   â”‚
â”‚ â€¢ Continue medication holds            â”‚
â”‚ â€¢ Optimize hemodynamics                â”‚
â”‚ â€¢ Nutrition support                    â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Monitor for recovery:                â”‚
â”‚ â€¢ Daily creatinine trending           â”‚
â”‚ â€¢ Urine output patterns               â”‚
â”‚ â€¢ Electrolyte stability               â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Recovery timeline:                   â”‚
â”‚ â€¢ Typically 1-3 weeks for recovery    â”‚
â”‚ â€¢ Monitor for complications            â”‚
â”‚                                         â”‚
â”‚ [Next: Complication monitoring â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Calculator Results]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4C â€“ Clinical Judgment (Node Indeterminate)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¤” INDETERMINATE RESULTS - CLINICAL JUDGMENTâ”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ” Additional considerations:           â”‚
â”‚ â€¢ Mixed prerenal + ATN possible        â”‚
â”‚ â€¢ Early ATN may have low FENa          â”‚
â”‚ â€¢ Contrast exposure timing             â”‚
â”‚ â€¢ Sepsis with prerenal + intrinsic     â”‚
â”‚                                         â”‚
â”‚ ğŸ¯ Approach:                            â”‚
â”‚ â€¢ Cautious fluid trial                 â”‚
â”‚ â€¢ Close monitoring of response         â”‚
â”‚ â€¢ Early nephrology consultation        â”‚
â”‚                                         â”‚
â”‚ â“ Clinical assessment suggests?        â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ LIKELY PRERENAL â†’ Cautious fluids   â”‚
â”‚ ğŸ”˜ LIKELY ATN â†’ Supportive care        â”‚
â”‚ ğŸ”˜ UNCLEAR â†’ Nephrology consult        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ Risk Stratification (Node Risk Assessment)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš–ï¸  AKI RISK STRATIFICATION             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Assess patient risk factors:         â”‚
â”‚ â€¢ Hypovolaemia                         â”‚
â”‚ â€¢ Acidosis (pH <7.35)                  â”‚
â”‚ â€¢ Pulmonary oedema                     â”‚
â”‚ â€¢ Uraemic encephalopathy               â”‚
â”‚ â€¢ Hyperkalaemia (K+ >5.5)              â”‚
â”‚                                         â”‚
â”‚ ğŸ”¬ Laboratory trend analysis:           â”‚
â”‚ â€¢ Rising creatinine velocity           â”‚
â”‚ â€¢ Electrolyte abnormalities            â”‚
â”‚ â€¢ Acid-base disturbances               â”‚
â”‚                                         â”‚
â”‚ â“ Risk level assessment?               â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ HIGH RISK â†’ Emergency management    â”‚
â”‚ ğŸ”˜ MODERATE â†’ Medical optimization     â”‚
â”‚ ğŸ”˜ LOW RISK â†’ Conservative care        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6A â€“ Emergency Management (Node High Risk â†’ Complications)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸš¨ EMERGENCY AKI MANAGEMENT             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Immediate priorities:                â”‚
â”‚ â€¢ Life-threatening complications first â”‚
â”‚ â€¢ Hyperkalaemia (K+ >6.5): CaÂ²âº + insulinâ”‚
â”‚ â€¢ Severe acidosis: Bicarbonate if pH<7.1â”‚
â”‚ â€¢ Pulmonary edema: Diuretics + CPAP    â”‚
â”‚ â€¢ Uremic complications: Consider RRT   â”‚
â”‚                                         â”‚
â”‚ ğŸ”„ Supportive measures:                 â”‚
â”‚ â€¢ PPI for GI bleeding prevention       â”‚
â”‚ â€¢ Phosphate monitoring                 â”‚
â”‚ â€¢ Anemia management                    â”‚
â”‚                                         â”‚
â”‚ â“ Emergent dialysis criteria (AEIOU)?  â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Dialysis evaluation           â”‚
â”‚ ğŸ”˜ NO â†’ Intensive monitoring           â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6B â€“ Medical Optimization (Node Moderate â†’ Monitoring)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’Š MEDICAL OPTIMIZATION PROTOCOL        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Systematic approach:                 â”‚
â”‚ â€¢ Optimize volume status               â”‚
â”‚ â€¢ Address underlying causes            â”‚
â”‚ â€¢ Prevent further injury               â”‚
â”‚ â€¢ Monitor for progression              â”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Enhanced monitoring:                 â”‚
â”‚ â€¢ Labs q12-24h based on stability      â”‚
â”‚ â€¢ I/O balance tracking                 â”‚
â”‚ â€¢ Daily weights                        â”‚
â”‚ â€¢ Medication level monitoring          â”‚
â”‚                                         â”‚
â”‚ [Next: Response monitoring â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Risk Stratification]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6C â€“ Conservative Care (Node Low Risk â†’ Follow-up)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ›¡ï¸  CONSERVATIVE AKI MANAGEMENT         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ’Š Standard supportive measures:        â”‚
â”‚ â€¢ Maintain drug holds appropriately    â”‚
â”‚ â€¢ Monitor fluid balance                â”‚
â”‚ â€¢ Regular laboratory surveillance      â”‚
â”‚ â€¢ Patient/family education             â”‚
â”‚                                         â”‚
â”‚ ğŸ“ˆ Recovery monitoring:                 â”‚
â”‚ â€¢ Daily creatinine until stable        â”‚
â”‚ â€¢ Trend toward baseline               â”‚
â”‚ â€¢ Resume medications when appropriate  â”‚
â”‚                                         â”‚
â”‚ [Next: Follow-up planning â–¶]           â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Risk Stratification]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7A â€“ Dialysis Evaluation (Node AEIOU Assessment)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”¬ EMERGENT DIALYSIS CRITERIA (AEIOU)   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš¨ Life-threatening indications:        â”‚
â”‚ â€¢ Acidosis: pH <7.2 refractory         â”‚
â”‚ â€¢ Electrolytes: K+ >6.5 refractory     â”‚
â”‚ â€¢ Intoxication: Dialyzable toxins       â”‚
â”‚   (methanol, ethylene glycol, lithium, â”‚
â”‚   salicylates, isopropanol)            â”‚
â”‚ â€¢ Overload: Pulmonary edema + hypoxia  â”‚
â”‚ â€¢ Uremia: Pericarditis, encephalopathy,â”‚
â”‚   bleeding diathesis                   â”‚
â”‚                                         â”‚
â”‚ â° Time-sensitive decision               â”‚
â”‚                                         â”‚
â”‚ â“ AEIOU criteria present?              â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Emergent RRT setup            â”‚
â”‚ ğŸ”˜ NO â†’ Continue intensive monitoring  â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7B â€“ Intensive Monitoring (Node Enhanced Surveillance - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ‘ï¸  INTENSIVE MONITORING PROTOCOL       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Enhanced surveillance:               â”‚
â”‚ â€¢ Labs q6-12h until stable             â”‚
â”‚ â€¢ Continuous cardiac monitoring        â”‚
â”‚ â€¢ Hourly urine output if catheterized  â”‚
â”‚ â€¢ Serial arterial blood gases          â”‚
â”‚                                         â”‚
â”‚ âš ï¸  Escalation triggers:                â”‚
â”‚ â€¢ K+ >6.0 despite treatment            â”‚
â”‚ â€¢ pH <7.25 or worsening               â”‚
â”‚ â€¢ Mental status changes               â”‚
â”‚ â€¢ Respiratory distress from overload   â”‚
â”‚                                         â”‚
â”‚ ğŸ“ Immediate nephrology if deteriorationâ”‚
â”‚                                         â”‚
â”‚ âœ… INTENSIVE MONITORING ACTIVE         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Dialysis Evaluation]      â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 8A â€“ Emergent RRT (Node RRT Setup â†’ Modality)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš¡ EMERGENT RENAL REPLACEMENT THERAPY   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸš€ Immediate actions:                   â”‚
â”‚ â€¢ STAT nephrology consultation         â”‚
â”‚ â€¢ ICU admission if unstable            â”‚
â”‚ â€¢ Prepare temporary vascular access     â”‚
â”‚ â€¢ Family communication                 â”‚
â”‚                                         â”‚
â”‚ âš™ï¸  Modality selection criteria:        â”‚
â”‚ â€¢ Hemodynamically stable â†’ IHD         â”‚
â”‚ â€¢ Unstable/pressors â†’ CRRT             â”‚
â”‚ â€¢ Large volume removal needed â†’ CRRT   â”‚
â”‚                                         â”‚
â”‚ â“ Patient hemodynamically stable?      â”‚
â”‚                                         â”‚
â”‚ ğŸ”˜ YES â†’ Intermittent hemodialysis     â”‚
â”‚ ğŸ”˜ NO â†’ Continuous RRT                 â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9A â€“ Intermittent Hemodialysis (Node IHD - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ©º INTERMITTENT HEMODIALYSIS PROTOCOL   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âš™ï¸ HD parameters:                       â”‚
â”‚ â€¢ Duration: 3-4 hours                  â”‚
â”‚ â€¢ Blood flow: 300-400 mL/min           â”‚
â”‚ â€¢ Dialysate flow: 500-800 mL/min       â”‚
â”‚ â€¢ UF rate: <13 mL/kg/h (hemodynamic tolerance)â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Anticoagulation protocol:            â”‚
â”‚ â€¢ Standard heparin: PTT 60-80s         â”‚
â”‚ â€¢ Heparin-free if bleeding risk        â”‚
â”‚ â€¢ Regional citrate for contraindicationsâ”‚
â”‚                                         â”‚
â”‚ ğŸ“Š Initial prescription conservative    â”‚
â”‚                                         â”‚
â”‚ âœ… INTERMITTENT HD INITIATED           â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: RRT Setup]                â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9B â€“ Continuous RRT (Node CRRT - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”„ CONTINUOUS RRT PROTOCOL              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âš™ï¸ CRRT parameters:                     â”‚
â”‚ â€¢ Blood flow: 150-200 mL/min           â”‚
â”‚ â€¢ Effluent rate: 25-35 mL/kg/h         â”‚
â”‚ â€¢ CVVHDF mode preferred                â”‚
â”‚ â€¢ Replacement fluid: Pre-dilution      â”‚
â”‚                                         â”‚
â”‚ ğŸ’Š Anticoagulation (regional citrate):  â”‚
â”‚ â€¢ Citrate infusion pre-filter          â”‚
â”‚ â€¢ Monitor ionized calcium q6h          â”‚
â”‚ â€¢ Contraindicated in liver failure     â”‚
â”‚                                         â”‚
â”‚ ğŸ¥ ICU-level monitoring required        â”‚
â”‚                                         â”‚
â”‚ âœ… CONTINUOUS RRT INITIATED            â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: RRT Setup]                â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9C â€“ Response Monitoring (Node Treatment Response - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ˆ TREATMENT RESPONSE MONITORING        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ¯ Recovery indicators:                 â”‚
â”‚ â€¢ Creatinine plateau/decline           â”‚
â”‚ â€¢ Urine output improvement             â”‚
â”‚ â€¢ Electrolyte normalization            â”‚
â”‚ â€¢ Resolution of uremic symptoms        â”‚
â”‚                                         â”‚
â”‚ ğŸ”„ Medication management:               â”‚
â”‚ â€¢ Gradual reintroduction of held meds  â”‚
â”‚ â€¢ ACE/ARB when creatinine stable       â”‚
â”‚ â€¢ Adjust doses for current GFR         â”‚
â”‚                                         â”‚
â”‚ ğŸ“… Transition planning:                 â”‚
â”‚ â€¢ Step-down from intensive monitoring  â”‚
â”‚ â€¢ Outpatient follow-up arrangement     â”‚
â”‚                                         â”‚
â”‚ âœ… RESPONSE MONITORING COMPLETE        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Medical Optimization]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 9D â€“ Follow-Up Planning (Node Discharge Planning - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“… POST-AKI FOLLOW-UP PROTOCOL          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ğŸ“Š Discharge readiness criteria:        â”‚
â”‚ â€¢ Creatinine stable or improving       â”‚
â”‚ â€¢ No ongoing complications             â”‚
â”‚ â€¢ Medication reconciliation complete   â”‚
â”‚ â€¢ Patient education completed          â”‚
â”‚                                         â”‚
â”‚ ğŸ”„ Outpatient monitoring plan:          â”‚
â”‚ â€¢ 1 week: Renal function check         â”‚
â”‚ â€¢ 3 months: CKD assessment if incompleteâ”‚
â”‚   recovery                             â”‚
â”‚ â€¢ Annual: CKD screening thereafter     â”‚
â”‚                                         â”‚
â”‚ ğŸ“š Patient education materials:         â”‚
â”‚ â€¢ AKI prevention strategies            â”‚
â”‚ â€¢ Nephrotoxin avoidance               â”‚
â”‚ â€¢ When to seek medical attention       â”‚
â”‚                                         â”‚
â”‚ âœ… FOLLOW-UP PROTOCOL ESTABLISHED      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Conservative Care]        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## ENHANCED FLOWCHART WITH CALCULATOR INTEGRATION
Initial AKI Assessment  
â†“  
AKI Criteria Met?  
â”œâ”€ YES â†’ Investigate AKI (Drug holds + Labs including urine electrolytes)  
â”‚ â†“  
â”‚ Etiology Determination  
â”‚ â”œâ”€ CLEAR ETIOLOGY â†’ Direct Management  
â”‚ â””â”€ PRERENAL vs ATN UNCLEAR â†’ Calculators  
â”‚ â”œâ”€ FENa Calculator  
â”‚ â””â”€ FEUrea Calculator  
â”‚ â”œâ”€ Prerenal â†’ Volume Resuscitation  
â”‚ â”œâ”€ ATN â†’ Supportive Care  
â”‚ â””â”€ Indeterminate â†’ Clinical Judgment  
â”‚ â†“  
â”‚ Risk Stratification  
â”‚ â”œâ”€ HIGH â†’ Emergency Management â†’ AEIOU?  
â”‚ â”‚ â”œâ”€ YES â†’ RRT  
â”‚ â”‚ â”‚ â”œâ”€ Stable â†’ IHD  
â”‚ â”‚ â”‚ â””â”€ Unstable â†’ CRRT  
â”‚ â”‚ â””â”€ NO â†’ Intensive Monitoring  
â”‚ â”œâ”€ MODERATE â†’ Medical Optimization â†’ Response Monitoring  
â”‚ â””â”€ LOW â†’ Conservative Care â†’ Follow-up Planning  
â””â”€ NO â†’ Monitor Function
## VIRTUA VOORHEES ENHANCED INTEGRATION

### Calculator Integration Specifications
**FENa Calculator (MDCalc Integration):**
- **Automated Population:** Pull serum values from EHR
- **Real-Time Calculation:** Dynamic result display
- **Clinical Decision Support:** Interpretation guidance
- **Documentation:** Auto-populate in clinical notes

**FEUrea Calculator (Enhanced Accuracy):**
- **Preferred When:** Diuretic use, CKD, elderly patients
- **Superior Specificity:** Better discrimination than FENa
- **Clinical Context Integration:** Consider with urinalysis findings

### Enhanced Diagnostic Protocol
**Urine Studies - Comprehensive Panel:**
STANDARD URINE WORKUP FOR AKI:  
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  
â”‚ ğŸ§ª COMPREHENSIVE URINE ANALYSIS â”‚  
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤  
â”‚ Basic Dipstick: â”‚  
â”‚ - Protein, blood, glucose, ketones â”‚  
â”‚ - Specific gravity, pH â”‚  
â”‚ â”‚  
â”‚ Microscopy (Fresh <2h): â”‚  
â”‚ - RBC casts â†’ Glomerulonephritis â”‚  
â”‚ - WBC casts â†’ Acute interstitial nephritisâ”‚  
â”‚ - Granular casts â†’ ATN â”‚  
â”‚ - Hyaline casts â†’ Normal/prerenal â”‚  
â”‚ â”‚  
â”‚ Electrolytes (if prerenal vs ATN unclear):â”‚  
â”‚ - Urine sodium, creatinine for FENa â”‚  
â”‚ - Urine BUN, creatinine for FEUrea â”‚  
â”‚ â”‚  
â”‚ Special Studies (if indicated): â”‚  
â”‚ - Protein:creatinine ratio â”‚  
â”‚ - Urine eosinophils â”‚  
â”‚ - Urine myoglobin â”‚  
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
### Clinical Decision Tree Integration
**Calculator Trigger Points:**
1. **Volume Status Unclear:** Physical exam equivocal
2. **Diuretic Use:** FEUrea more accurate than FENa
3. **Mixed Picture:** Clinical and lab findings discordant
4. **Early ATN:** May still have low FENa initially

### Quality Improvement Integration
**Process Measures:**
- Calculator utilization rate in appropriate cases
- Time from AKI recognition to etiology determination
- Accuracy of prerenal vs ATN differentiation
- Appropriate fluid management response

**Outcome Measures:**
- Reduction in inappropriate fluid administration
- Improved diagnostic accuracy
- Decreased time to appropriate therapy
- Reduced AKI progression

### System Integration Features
**EHR Calculator Embedding:**
CLINICAL DECISION SUPPORT INTEGRATION:  
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”  
â”‚ Smart Calculator Triggers: â”‚  
â”‚ - Auto-suggest when urine lytes ordered â”‚  
â”‚ - Pop-up when AKI + bland sediment â”‚  
â”‚ - Integration with order sets â”‚  
â”‚ â”‚  
â”‚ Results Interpretation: â”‚  
â”‚ - Color-coded results (Green/Yellow/Red)â”‚  
â”‚ - Automatic clinical recommendations â”‚  
â”‚ - Link to management protocols â”‚  
â”‚ â”‚  
â”‚ Documentation Support: â”‚  
â”‚ - Auto-populate assessment section â”‚  
â”‚ - Generate plan recommendations â”‚  
â”‚ - Track calculator utilization â”‚  
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Advanced Features
**Calculator Enhancements:**
- **Pediatric Adjustments:** Age-appropriate normal values
- **CKD Modifications:** Baseline-adjusted interpretations  
- **Drug Interaction Alerts:** When diuretics affect results
- **Trending Capability:** Serial calculations over time

**Clinical Context Integration:**
- **Sepsis Modifier:** Adjust thresholds in septic AKI
- **Heart Failure Integration:** Consider cardiorenal physiology
- **Medication Timeline:** Link to nephrotoxin exposure timing
- **Recovery Tracking:** Monitor trends during treatment response

## REFERENCE GUIDELINES & CALCULATOR SOURCES
- **2024 KDIGO Acute Kidney Injury Guidelines**
- **2019 AAFP Clinical Guidelines for AKI**
- **2023 KDOQI Hemodialysis Guidelines**
- **MDCalc FENa Calculator:** https://www.mdcalc.com/fractional-excretion-sodium-fena
- **MDCalc FEUrea Calculator:** https://www.mdcalc.com/fractional-excretion-urea-feurea
- **Clinical Protocol Integration (Evidence-Based Practice)**
- **Virtua Health System AKI Protocol v2024**

**This final version integrates the FENa and FEUrea calculators as dynamic, interactive cards within the clinical decision-making process, enhancing diagnostic accuracy and providing real-time clinical decision support for optimal AKI management.**
